CVS Health announced on Tuesday plans to split into two independent, publicly traded companies, with the separation expected to be completed by the first half of 2028 [1]. The restructuring will create a healthcare solutions company retaining the CVS Health name, which will house its pharmacy benefit manager (PBM) insurance plans and subsidiaries including Aetna, CVS Caremark, CVS Specialty, Oak Street Health, and Signify Health [1]. The separate CVS Pharmacy retail division will operate approximately 9,000 stores, its mail-order pharmacy business, MinuteClinic, and the Health100 technology services unit [1]. Existing CVS Health investors will receive shares in both companies on a tax-free basis [1].
The market reacted negatively to the announcement, with CVS shares plunging nearly 13% on Tuesday, reaching levels not seen since spring, closing at $79.96 with a decline of $11.45 or -12.53% [1]. However, industry experts view the breakup favorably from a competitive standpoint. Douglas Hoey of the National Community Pharmacists Association (NCPA) stated that the separation "will be good for competition, good for patients, lower prices, good for small businesses to be able to compete against these conglomerates" [1]. Hoey noted that the breakup could create a more level playing field for independent pharmacies against the retail pharmacy giant [1].
The separation may result in increased store closures for the standalone CVS Pharmacy business. Hoey predicted that as an independent entity, CVS will "look even more closely at underperforming stores and want to close underperforming stores," noting that the company has shuttered roughly 10% of its locations over the past five years due to underperformance [1]. However, Hoey added that "most of the time CVS's are located near other pharmacies" and patients typically have alternative options when a location closes [1]. The breakup addresses broader competitive concerns, as only about one-third of pharmacies nationwide are independently owned, with CVS's competitive practices having contributed to independent pharmacy closures [1].
CONCLUSION
CVS's planned breakup into separate pharmacy and health insurance entities represents a significant structural transformation expected by mid-2028, initially triggering a sharp 12.53% stock decline despite industry experts viewing it as beneficial for competition and consumer costs. The separation could reshape the competitive landscape by reducing the conglomerate's integrated advantages, though it may accelerate store closures in underperforming markets as the standalone pharmacy business optimizes its footprint.